Library
Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
1 December 2013. doid: 10.1111/bcp.12141
Klumpers LE, Fridberg M, de Kam ML, Little PB, Jensen NO, Kleinloog HD, Elling CE, van Gerven JM
View publicationCannabinoid receptor type 1 (CB1 ) antagonists show central side effects, whereas beneficial effects are most likely peripherally mediated. In this study, the peripherally selective CB1 antagonist TM38837 was studied in humans.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
